echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > Several health-care negotiating varieties that deserve attention outside of PD-1

    Several health-care negotiating varieties that deserve attention outside of PD-1

    • Last Update: 2021-01-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The outcome of the 2020 health care negotiations is about to be announced.
    addition to the seven PD-1 varieties that have attracted so much attention, what else is worth our attention? Here are some for informational purposes only.
    NO.1 PCSK9 inhibitors - Alisiyu monoanti, eloyu monolithic PCSK9 Chinese full name "pre-protein-converting enzyme oxalolysis/Kexin 9", is the most reliable target for lipid-lowering drugs after his statins.
    PCSK9 binds to LDLR, reducing the liver's ability to remove LDL-C (LDL-C), also known as bad cholesterol, from the blood.
    's Repatha (Eloyu monoanti) and Sanofi's Praluent (Aliciu monoanti) were approved in the European Union and the United States in July 2015, respectively, the former preferred adaptive disorder is the rare disease pure-group familial hypercholesterolemia (HoFH), the latter from the hyper-adaptive atherosclerosis cardiovascular disease (ASCVD).
    Eloyod was approved by the NMPA in July 2018 for the treatment of HoFH in adults or over 12 years of age, and later approved for the treatment of primary hypercholesterolemia and mixed lipid abnormalities, as well as the treatment of atherosclerotic cardiovascular disease; Lisiyu monoantigen was approved by NMPA in December 2019 for cardiovascular event prevention in patients with atherosclerosis cardiovascular disease, as well as treatment for reducing LDL-C levels in primary hair hypercholesterolemia (heterozobacteria and non-familial) and mixed lipid abnormalities.
    pricing, Aliciu monoantigen currently in the domestic price of 1888 yuan / 75 mg, every 2 weeks subsulation injection 75 mg, if the patient needs to reduce LDL-C more substantially, can be adjusted to the maximum dose (150 mg per 2 weeks);
    the current price of 1298 yuan / 0.14g in China, for HoFH patients, need to inject 0.42g per month;
    the annual usage costs of the two are comparable.
    market performance, Alyssiu's global sales in 2019 were EUR 258 million, while its global sales in the first half of 2020 were EUR 146 million, while Eloyod's net profit was EUR 661 million in 2019 and US$429 million in the first half of 2020.
    NO.2 antibody co-linked drugs - Enmetrotumab, Vibutoxi monoantibody coupled (ADC) advantages of both antibody drugs precision targeting, and small molecule cytotoxic drugs of the powerful lethal effect, equivalent to the destruction of small molecules equipped with precision-guided warheads, so the industry image is likened to "biological missiles."
    The enmetrophic bead monoantigen, developed by Roche and ImmunoGen, is a chemotherapy drug that targets HER2 and inhibits micro-tube aggregation, Metanxin (DM1), via the thioether connecter MCC, in 2020 Approved by NMPA in January 2001, the commodity name Kadcyla is the first approved ADC drug approved for market in China, suitable for the treatment of HER2-positive early breast cancer patients who still have invasive lesions after receiving a new complementary treatment based on the combined octopaedic monotherapy of yew alkanes.
    breast cancer is the most common cancer in women 40 years, of which about 25% to 30% of breast cancer has HER2 over-expression.
    Enmetro Bead Mono-Resistance is another heavyweight product that consolidates its dominance in HER2, following the Curto-Bead Mono-Resistance and Pato-Pearl Single-Resistance.
    three heavy-duty drugs have changed the treatment pattern for HER2-positive breast cancer.
    Enmequo single anti-listing two specifications, in the domestic price is 19282 yuan / 100mg, 27633 yuan / 160mg, the dose of 3.6mg / kg, every 3 weeks, early breast cancer patients need to receive 18 cycles of treatment.
    this calculation, the cost of a course of treatment for an ordinary adult patient (60 kg) is close to 840,000 yuan.
    November 28, 2019, Quto Zhu single resistance successfully renewed through the national health care negotiations, Pato Zhu single resistance also entered the national health insurance for the first time in 2019, Enmei Quzhu single resistance through negotiations into health insurance is also very likely.
    , NMPA approved the second ADC drug, the injectable vibutoxi monoantigen, developed by Takeda Pharmaceuticals, on May 12, 2020.
    This is a monoclonal antibody targeting CD30 connected to a micro-tube-suppressing cytotoxic drug (monomedehylastatin E, MMAE) that stabilizes the presence in the blood and precisely kills the ADC of tumor cells that express CD30.
    Vibtoxi monoantigen currently in the domestic price of 22,000 yuan / 50 mg, patients every 3 weeks intravenous injection of 1.8 mg / kg, up to 16 cycles, then an ordinary adult patient (60 kg) annual use costs of more than 700,000 yuan.
    NO.3-day-price orphan drug - Nosine sodium spinal amyotrophic amyotrophic disease is a rare common chromosomal recessive genetic disease caused by mutations in the motor neuron survival gene 1 (SMN1) caused by defects in the function of the SMN protein.
    SMA is characterized by degenerative degeneration and loss of motor neurons in the frontal corner of the spinal cord.
    SMA incidence rate is 1/10 000 to 1/6000, carrying rate is 1/50 to 1/40, china does not have epidemiological data on SMA incidence.
    sodium injection is an antonym oligonucleotide (ASO) that alters the shearing of mRNA before SMN2, thereby increasing the production of full-length SMN proteins.
    product, developed by Biogen and first approved in the U.S. in December 2016, is the world's first SMA precision-targeted treatment.
    February 2019, the Nosinasi sodium injection was officially approved by NMPA for the treatment of 5q spinal muscular dystrophy (SMA) and became the first drug in China to treat spinal muscular dystrophy (SMA).
    5q SMA is the most common form of the disease, accounting for about 95% of all SMA cases.
    Nosinas sodium injection is currently priced at 697,000 yuan per unit in China, the dose is given on the first day, 14, 28, 63 days to give 4 load doses, after which 1 maintenance dose is given every 4 months.
    this calculation, the annual cost of treatment for an ordinary adult patient is about $4.2 million.
    the product set a new record for the price of a Chinese drug, with the exception of a handful of cities that list rare diseases as commercially insured, and the Nosinasi sodium injection is a fully out-of-the-way drug in the country.
    NO.4 China approved the first dual-anti-Amesai bead single-specific antibody (BsAb) refers to the antibody molecules that can be specifically binding two antigens or two tables at the same time, theoretically can play a synergy between the two single-anti-combination, is currently one of the industry's most popular new drug research and development investment direction.
    Hemlibra is a recombinant humanized IgG4 dual-specific antibody developed by Roche/Chugai that simulates clotting factor VIIIa in the body by bridging the coagulation factor IXa and coagulation factor X to restore blood clotting in patients with type A haemophilia.
    haemophilia is a recessive genetic disease of X chromosome chain, which was included in the "First Rare Diseases List" in China in 2018, and the number of cases in China exceeds 100,000, of which 80% to 85% of the morbidity type is type A haemophilia, which causes blood to fail to solidify normally due to the lack of clotting factor VIII, prone to uncontrolled and frequent persistent or spontaneous bleeding.
    , which was approved by the FDA in November 2017, contributed CHF 1.38 billion in revenue to Roche in 2019 and more than CHF 1 billion in global sales in the first half of 2020.
    In China, the drug was approved by NMPA in December 2018 for the prevention of bleeding for haemophilia type A with coagulation factor VIII inhibitors, and Chinese commodity named Shu Youleli is the first dual-specific antibody drug approved for listing in China.
    in November 2019, The Emmys entered the national health-care negotiating list for the first time, but ultimately failed to do so.
    In September of this year, CDE announced its plan to include in the priority review and approval of the second application for the listing of the second adaptive disorder, which is routine preventive treatment for adult and child patients with type A haemophilia (congenital coagulation factor VIII deficiency) who do not have coagulation factor VIII inhibitors.
    According to patient feedback: Amesai bead monoantigen currently in the domestic price of 8100 yuan / 30 mg, the recommended dose is the first 4 weeks 3 mg / kg once a week (load dose), followed by 1.5 mg / kg once a week (maintained dose), by subdermal injection.
    , the annual cost of using an average adult patient (60kg) is close to $1.36 million.
    high cost of treatment has put a lot of haemophilia patients at a loss, and some haemophilia patients' organizations are clamouring for it to be included in health care as soon as possible.
    No.5 liver cancer first-line treatment targeted drug - lenphatinial liver cancer is the world's second largest cause of cancer death, liver cancer deaths each year about 750,000 cases.
    about 780,000 new cases of liver cancer are diagnosed globally each year, 80% of them in Asian countries such as China and Japan.
    about 85% to 90% of primary liver cancer.
    There are many treatment methods for early hepatocellular carcinoma, including surgery, radio frequency ablation, ethanol injection, chemotherapy embolism, etc., but for hepatocellular carcinoma, which cannot be surgically removed, treatment options are very limited, the prognosis is very poor, and the medical needs are far from being met.
    is a multi-target kinase inhibitor developed jointly by Wesser and Mercado, which blocks a range of regulatory factors in tumor cells, including VEGFR1-3, FGFR1-4, PDGFR alpha, KIT, RET, and so on.
    the product was approved by the FDA in February 2015 as a priority review and orphan drug for the treatment of high-risk differentiated thyroid cancer with radioactive iodine.
    was approved for treatment of advanced renal cell carcinoma, liver cancer and advanced endometrial cancer.
    , in China, lenvatinib was approved by NMPA in September 2018 for the treatment of liver cancer, and in November this year, the treatment of thyroid cancer was approved for the second adaptation.
    patents for lenfortinist compounds will expire in October 2021, and eight generic drug companies are currently on the market.
    revenues of 112 billion yen and $404 million for Wesfarmers and Mercadon in 2019.
    is the second targeted drug approved for first-line treatment of hepatocellular carcinoma after Soraphini, and the second listed first-line targeted treatment drug for liver cancer in China.
    currently sold in China for 560 yuan / 4mg / grain, weight less than 60 kg hepatocellular carcinoma patients dosing dose of 2 capsules per day, 1 time a day.
    this calculation, the annual cost of treatment for an adult patient weighing less than 60 kg is about 410,000 yuan.
    no.6 breast cancer, the country's first CDK4/6 inhibitor, is the number one malignant tumor that poses a serious threat to women's health worldwide.
    2015, there were 272,000 new cases of breast cancer and more than 70,000 deaths in China.
    the situation of advanced breast cancer is even more serious, each year, 1 in 10 new patients are diagnosed with advanced stage, and in the early breast cancer patients who have underwent surgery and standardized treatment, 30% to 40% will develop advanced breast cancer.
    of patients with advanced breast cancer is only 2-3 years, the five-year survival rate is only about 20%, there is an urgent need for innovative treatment options.
    cycle protein-dependent kinases 4 and 6 (CDK4/6) are key regulatory factors in cell division cycles and can drive cell division.
    CDK4/6 is an iconic feature of cancer because it is overactive in many cancers, causing the cell division cycle to spiral out of control.
    is a CDK4/6 inhibitor developed by Pfizer that blocks tumor cell proliferation by inhibiting CDK4/6 recovery cell cycle control.
    was approved by the FDA in February 2015 for the initial endocrine treatment of localized advanced or metastatic breast cancer in post-menopaian women who are positive for hormone-like (HR) and negative for human skin growth factor 2 (HER2) with aromatic enzyme inhibitors.
    continued to grow since its launch, contributing $4.96 billion in revenue to Pfizer in 2019.
    there are 3 specifications, 75 mg, 100 mg and 125 mg, the recommended daily dose of 125 mg, 1 time a day, the dosage method for continuous use for 21 days, after 7 days of suspension, 28 days for a treatment cycle.
    initial price of 125mg is 1420 yuan, according to this calculation, the annual treatment cost of an ordinary adult patient is about 387,000 yuan.
    , the drug was approved in July 2018 and has domestic sales of 64 million yuan in 2019.
    it is worth mentioning that Qilu, the first sound of the apipasili generic drug is also in the production stage.
    , even if Mr. Persilly does not plan to cut prices to get into health insurance, it will face greater risks in the future.
    NO.7 The first new drug for lupus in 60 years, Bellevue monosy systemic lupus (SLE), is the most common (approximately 70%) and most severe of all types of lupus, with clinical manifestations including large areas of red rash, fever, pain, kidney damage, respiratory and nervous system injuries, and so on.
    is the only biologic agent developed by GSK in nearly 60 years and the only biological agent available for the treatment of SLE in children.
    the product was approved by the FDA in March 2011 to treat autoantibo-positive adult SLE patients, and then expanded to include pediatric SLE patients over 5 years of age.
    has continued to grow since its launch, with global sales of 613 million pounds in 2019.
    in
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.